MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 February 2026 As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
26 February 2026 In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
25 February 2026 The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.
